Catalog

Record Details

Catalog Search


Back To Results
Showing Item 1 of 2

Bad blood : secrets and lies in a Silicon Valley startup  Cover Image Book Book

Bad blood : secrets and lies in a Silicon Valley startup

Carreyrou, John (author.).

Record details

  • ISBN: 9781524731656
  • Physical Description: x, 339 pages ; 24 cm
    print
  • Edition: First edition.
  • Publisher: New York : Alfred A. Knopf, 2018.

Content descriptions

General Note:
"This is a Borzoi book."
Bibliography, etc. Note: Includes bibliographical references and index.
Subject: Fraud United States
Hematologic equipment industry United States
Theranos (Firm) History

Available copies

  • 1 of 1 copy available at Town of Hanover Libraries.

Holds

  • 0 current holds with 1 total copy.

Holds

0 current holds with 1 total copy.

Show Only Available Copies
Location Call Number / Copy Notes Barcode Shelving Location Status Due Date
Howe Library 338.768 CAR 31254003526841 Lower level Available -

Syndetic Solutions - Summary for ISBN Number 9781524731656
Bad Blood : Secrets and Lies in a Silicon Valley Startup
Bad Blood : Secrets and Lies in a Silicon Valley Startup
by Carreyrou, John
Rate this title:
vote data
Click an element below to view details:

Summary

Bad Blood : Secrets and Lies in a Silicon Valley Startup


NATIONAL BESTSELLER * The gripping story of Elizabeth Holmes and Theranos--one of the biggest corporate frauds in history--a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword. "Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection." -- The New York Times Book Review In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.5 billion. There was just one problem: The technology didn't work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings--from journalists to their own employees.
Back To Results
Showing Item 1 of 2

Additional Resources